These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29237959)

  • 21. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.
    Nishihori T; Baz R; Shain K; Kim J; Ochoa-Bayona JL; Yue B; Sullivan D; Dalton W; Alsina M
    Eur J Haematol; 2015 Nov; 95(5):426-35. PubMed ID: 25600676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
    White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
    Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.
    Rosenthal A; Kumar S; Hofmeister C; Laubach J; Vij R; Dueck A; Gano K; Stewart AK
    Br J Haematol; 2016 Jul; 174(2):323-5. PubMed ID: 26403323
    [No Abstract]   [Full Text] [Related]  

  • 24. Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.
    Wu S; Zheng C; Chen S; Cai X; Shi Y; Lin B; Chen Y
    Biomed Res Int; 2015; 2015():927105. PubMed ID: 26425561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
    Tessenow H; Holzvogt M; Holzvogt B; Andrea M; Heyn S; Schliwa T; Schwarz M; Zehrfeld T; Becker C; Pfrepper C; Franke GN; Krahl R; Jentzsch M; Leiblein S; Schwind S; Bill M; Vucinic V; Lange T; Niederwieser D; Pönisch W
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2049-2058. PubMed ID: 28534173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bilateral phrenic nerve palsy induced by subcutaneous bortezomib in a patient with newly diagnosed multiple myeloma: first case reported.
    López M; Martínez Lacasa X; Martí JM; Muntañola A; Fernández M; Huertas S; Saumell S; De Diego I; Bustamante G; Mesa A; Canet M; Julià M; Vall-Llovera F
    Leuk Lymphoma; 2017 Feb; 58(2):482-484. PubMed ID: 27348085
    [No Abstract]   [Full Text] [Related]  

  • 28. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
    Siegel DS; Dimopoulos M; Jagannath S; Goldschmidt H; Durrant S; Kaufman JL; Leleu X; Nagler A; Offner F; Graef T; Eid JE; Houp J; Gause C; Vuocolo S; Anderson KC
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):329-334.e1. PubMed ID: 27025160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
    Dunn TJ; Dinner S; Price E; Coutré SE; Gotlib J; Hao Y; Berube C; Medeiros BC; Liedtke M
    Br J Haematol; 2016 Apr; 173(2):253-9. PubMed ID: 27040320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.
    Qin XY; Lu J; Li GX; Wen L; Liu Y; Xu LP; Chang YJ; Liu KY; Jiang ZF; Huang XJ
    Ann Hematol; 2018 Mar; 97(3):485-495. PubMed ID: 29264740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.
    Castro TB; Hallack Neto AE; Atalla A; Ribeiro LC
    Braz J Med Biol Res; 2016; 49(6):e5128. PubMed ID: 27254660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
    Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
    Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
    Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC
    Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
    Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
    Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.
    Reece DE; Trieu Y; Masih-Khan E; Atenafu EG; Chen C; Prica A; Tiedemann R; Trudel S; Kukreti V
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):387-94. PubMed ID: 27349765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
    Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K
    Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387
    [No Abstract]   [Full Text] [Related]  

  • 37. Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens.
    Hyun SY; Han SH; Kim SJ; Jang JE; Kim Y; Cho H; Lee JY; Cheong JW; Min YH; Song JW; Kim JS
    J Korean Med Sci; 2016 Apr; 31(4):510-8. PubMed ID: 27051233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
    Bao L; Lu XJ; Zhang XH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.